drugset

drugset / Trial / NCT06132256

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06132256 ↗

Phase 2 Active not recruiting 145 enrolled Syndax Pharmaceuticals DevPro Biopharma · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will evaluate the efficacy and safety of axatilimab in participants with IPF.

Timeline

Start: 2023-12-11
Primary completion: 2026-09
Completion: 2026-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Axatilimab	Monoclonal antibody	—	Intravenous

Indications